The effect of modest alcohol consumption on fibrosis progression in the general population with nonalcoholic fatty liver disease (NAFLD) remains unclear. We examined the association of nonheavy alcohol consumption with worsening of noninvasive fibrosis indices in a large-scale, low-risk population with NAFLD. A cohort study was performed in 58,927 Korean adults with NAFLD and low fibrosis scores who were followed for a median of 4.9 years. Non-, light, and moderate drinkers were defined as 0 g/day, 1-9.9 g/day, and 10-29.9 g/day (10-19.9 g/day for women), respectively. Progression from low to intermediate or high probability of advanced fibrosis was assessed using noninvasive indices including NAFLD fibrosis score (NFS) and Fibrosis-4 Index (FIB-4). A parametric proportional hazards model was used to estimate the multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). 
per se, is the most important histologic predictor of liver and nonliver-related mortality. (3) (4) (5) (6) (7) Identification of modifiable risk factors associated with advanced fibrosis is therefore important for any preventive strategies against liver and nonliver complications related to NAFLD.
The effects of alcohol consumption, a modifiable risk factor, on liver disease differ depending on the level of alcohol consumption. While heavy alcohol drinking is known to have many detrimental effects, whether patients with NAFLD can be allowed nonheavy alcohol consumption remains controversial. (8, 9) Previous cross-sectional studies in patients with biopsy-proven NAFLD have reported that modest alcohol consumption is associated with less severe histology and fibrosis, (10, 11) whereas another cross-sectional study showed no association. (12) However, these cross-sectional studies can be limited by ambiguous temporality and reverse causation between exposure and outcome. This is important because persons with more severe liver disease may be more likely to abstain from alcohol as a result of their liver disease. (9) Furthermore, patients with biopsy-proven NAFLD are not representative of subjects with NAFLD in the general population, and the effect of nonheavy alcohol consumption on fibrosis progression in the general population with NAFLD remains unclear. Until now, no large-scale longitudinal cohort studies have evaluated whether modest alcohol consumption affects fibrosis progression in low-risk individuals with NAFLD.
We performed a longitudinal cohort study in young and middle-aged Korean men and women with NAFLD to examine the association between nonheavy alcohol consumption and the risk of worsening of noninvasive fibrosis markers while accounting for time-dependent measures of change in alcohol consumption and other covariates during follow-up.
Participants and Methods

StUDy popUlatIoNS
The Kangbuk Samsung Health Study is a cohort study of Korean men and women aged 18 years and older who completed comprehensive annual or biennial examinations at Kangbuk Samsung Hospital Total Healthcare Center in Seoul or Suwon, South Korea. (13, 14) Most examinees (over 80%) are employees of various companies and local governmental organizations, or the spouses of employees. In South Korea, the Industrial Safety and Health Law requires annual or biennial health screening examinations of all employees, free of charge. Other examinees voluntarily underwent health checkups at the health care center.
aRtICle INFoRMatIoN:
The total number of participants who underwent a comprehensive health examination between January 2002 and December 2017 and had at least 1 follow-up visit through December 31, 2017, was 352,795. Our analysis was restricted to all study participants with fatty liver on abdominal ultrasonography at baseline (n = 90,439) ( Figure 1 ). Because the diagnosis of NAFLD is a diagnosis of exclusion, we excluded participants for the following criteria: alcohol intake ≥30 g/day for men and ≥20 g/day for women (n = 13,315) (1) ; positive serologic markers for hepatitis B or C virus (n = 2,999); known liver disease or use of medications for liver disease (n = 4,317); and use of steatogenic medications within the past year, such as valproate, amiodarone, methotrexate, tamoxifen, or corticosteroids (n = 232).
(1) For this analysis to evaluate the effect of nonheavy alcohol consumption on the development of intermediate or high fibrosis score among 72,554 subjects with NAFLD, we excluded those with intermediate or high probability of fibrosis based on Fibrosis-4 Index (FIB-4), NFS, or aspartate aminotransferase-to-platelet ratio index (APRI) at baseline (n = 10,255) or history of liver cirrhosis or findings of liver cirrhosis on ultrasonography (n = 1). Finally, out of 62,299 NAFLD subjects free of outcome, subjects with a history of malignancy (n = 623) and those with missing information on weight and components of FIB-4, NFS, and APRI including glucose, albumin, aspartate aminotransferase (AST), alanine transaminase (ALT), and platelet counts (n = 2,830) were excluded. Because some individuals met more than one exclusion criterion, a total of 58,927 participants were included in the analysis.
The Institutional Review Board of Kangbuk Samsung Hospital approved this study, and informed consent was waived because de-identified retrospective data from a routine health screening process were used.
MeaSUReMeNtS
Data on physical measurements, abdominal ultrasonography, and serum biochemical measurements were collected as a part of the basic health check-up program at each visit. Demographic characteristics, health behaviors, medical history, and medication use were also collected at each visit using standardized, self-administered questionnaires as previously described. (14) Participants were categorized by smoking status as never, former, and current smokers. The questionnaire asked about the frequency of alcohol drinking and amount of alcohol consumed on a single occasion. (15) Average alcohol consumption per day was calculated using frequency and amount of beverage consumed per drinking day. Nondrinking, light drinking, and moderate drinking were defined as 0 g/day, 1 to <10 g/day, and 10 to <20 g/day for women and 0 g/day, 1 to <10 g/day, and 10 to <30 g/ day for men, respectively. The weekly frequency of moderate-or vigorous-intensity physical activity was also assessed. Sitting blood pressure (BP), height, and weight were measured by trained nurses. Height was measured by stadiometer with participants wearing light clothing and no shoes. Weight was measured to the nearest 0.1 kg on a digital weight scale. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared (kg/m 2 ), and obesity was defined as BMI 25 kg/m 2 , the proposed cutoff for diagnosis of obesity in Asian populations. (16) Diabetes mellitus was defined as fasting serum glucose ≥126 mg/dL, self-reported use of insulin, or antidiabetic medications. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current use of antihypertensive medication.
Serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, AST, ALT, gamma-glutamyltransferase (GGT), fasting glucose, uric acid, high-sensitivity C-reactive protein (hsCRP), serum albumin, and platelet counts were measured as described in detail elsewhere. (13, 14) The homeostasis model assessment of insulin resistance (HOMA-IR) for quantifying insulin resistance was calculated as (fasting glucose × fasting insulin)/22.5.
The diagnosis of fatty liver was based on abdominal ultrasound using a Logic Q700 MR 3.5 MHz transducer, operated by experienced radiologists who were blinded to the aim of the present study. Images were produced in standard fashion with patients in the supine position with their right arm raised above their head. (17) Ultrasonographic diagnosis of fatty liver was determined based on known standard criteria, including presence of a diffuse increase of fine echoes in the liver parenchyma compared with kidney or spleen parenchyma, deep beam attenuation, and bright vessel walls. (18) NAFLD was defined as the presence of fatty liver in the absence of excessive alcohol use (threshold of <20 g/day for women and <30 g/day for men) (1) or other identifiable causes, as described in the exclusion criteria.
To assess the status of fibrosis progression in NAFLD according to alcohol consumption, three noninvasive indices of liver fibrosis were used: NAFLD fibrosis score (NFS), FIB-4, and APRI. NFS was calculated according to the following published formula: NFS = −1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m 2 ) + 1.13 × impaired fasting glycemia or diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio -0.013 × platelet (×10 9 /L) -0.66 × albumin (g/ dL). (19, 20) Two cutoff points were selected to categorize subjects with NAFLD into 3 groups according to probability of advanced fibrosis: high (NFS > 0.676), intermediate (NFS: 0.676 to −1.455), and low (NFS < −1.455). (20) FIB-4 was calculated with the following formula:
). For histologically defined NASH with advanced fibrosis, the area under the receiver-operating characteristic curve, sensitivity, and specificity of FIB-4 are 0.86 (95% CI, 0.78-0.94), 85%, and 65%, respectively. (21) Cutoff values from the curve were used to define low (FIB-4 < 1.30), intermediate, and high (FIB-4 ≥ 2.67) probability of advanced fibrosis. (22) APRI was calculated by the following formula: APRI = 100× (AST/upper limit of normal) / platelet count (×10 9 /L). Cutoffs for low and high probability of advanced fibrosis were 0.5 and 1.5, respectively. (23) 
StatIStICal aNalySIS
The χ 2 test and one-way ANOVA were used to analyze statistical differences between the characteristics and categories of alcohol consumption. The primary endpoint was the development of worsening (from low to intermediate or to high) probability of advanced fibrosis based on noninvasive fibrosis markers including FIB-4, NFS, and APRI. If an individual's noninvasive fibrosis markers worsened to meet the higher category (intermediate or high) during the follow-up, the case was assumed to have gotten worse, and subsequent measurements were not incorporated in the primary analysis, because liver condition can also affect alcohol consumption. Person-years were calculated as the sum of the follow-up duration from baseline until worsening of noninvasive fibrosis markers or until the final examination was conducted (prior to December 31, 2017), whichever came first.
Incidence rates were calculated as the number of incident cases divided by person-years of follow-up. Since the progression from low fibrosis score to higher scores was known to have developed between the 2 visits but the precise time at which it developed was unknown, a parametric proportional hazards model was used to account for this type of interval censoring (stpm command in Stata). (24) In these models, the baseline hazard function was parameterized with restricted cubic splines in log time with 4 degrees of freedom.
The HR and 95% CI were calculated for development of intermediate to high fibrosis scores according to alcohol consumption. Data were initially adjusted for age and sex and then further adjusted for center (Seoul or Suwon), year of screening exam, smoking status (never, past, current, or unknown), regular exercise (<3 times per week, ≥3 times per week, or unknown), education level (high school graduate or less, community college or university graduate, graduate school or higher, or unknown), BMI, history of diabetes, history of hypertension, medication for hypertension, medication for diabetes, and medication for dyslipidemia (Model 1). Model 2 was further adjusted for HOMA-IR and hsCRP. The proportional hazards assumption was assessed by examining graphs of estimated log (-log) survival. To determine linear trends of incidence, the number of categories was used as a continuous variable and tested on each model. To evaluate the impact of change in alcohol consumption and covariates over follow-up, we conducted additional analyses introducing alcohol consumption and other covariates as a time-varying covariate in the models. To exclude the effect of binge drinking, we performed analyses of participants who did not consume 60 g or more of alcohol on one occasion, because several studies reported that a binge-drinking pattern is another risk factor for fibrosis progression, even if average alcohol consumption falls into the moderate drinking category. (9, 25, 26) We conducted a series of sensitivity analyses to test the robustness of our primary results. First, we examined the association between nonheavy alcohol consumption and the risk of worsening (low to high) fibrosis scores using only high fibrosis score as an endpoint (instead of a composite endpoint of either intermediate or high fibrosis scores). Second, we examined the association between nonheavy alcohol consumption and persistent worsening of noninvasive markers of advanced fibrosis when intermediate or high fibrosis scores were repeatedly observed after the first occurrence of progression from low to intermediate or high fibrosis scores. Third, we examined the association between nonheavy alcohol consumption and worsening of noninvasive markers of advanced fibrosis after excluding participants with regression of NAFLD based on follow-up ultrasonography. Fourth, to exclude the effect of binge drinking, analyses of participants who did not consume 60 g or more of alcohol on one occasion were performed. Finally, stabilized inverse probability weights analysis was performed to reduce the confounding effects of other factors in the evaluation of the association between alcohol intake category and fibrosis progression. We used a fitted multinomial logistic regression to estimate each subject's probability of being in their own alcohol category conditional on the observed confounders. Stabilized weights were then calculated as the inverse of the estimated conditional probabilities of exposure, further rescaled based on the overall proportion of subjects in each alcohol category to reduce the variability of weights across category and to avoid influential observations with extremely large weights. (27) Predefined subgroup analyses were performed by age (<50 vs. ≥50 years), sex (men vs. women), smoking status (noncurrent smokers vs. current smokers), regular exercise (<3 vs. ≥3 time per week), diabetes mellitus (no vs. yes), hsCRP (<1.0 vs. ≥1.0 mg/L), HOMA-IR (<2.5 vs. ≥2.5), and menopause (no vs. yes). Interactions between alcohol consumption and subgroup characteristics were tested using likelihood ratio tests comparing models with versus without multiplicative interaction terms.
Statistical analyses were carried out using STATA version 15.0 (StataCorp LP, College Station, TX, USA). All P values lower than 0.05 were considered statistically significant.
Results
Baseline characteristics of 58,927 participants with NAFLD and a low probability of advanced fibrosis based on FIB-4, NFS, and APRI at baseline are presented according to alcohol consumption category (Table 1 ). The mean (SD) values for FIB-4, NFS, and APRI at baseline were 0.64 (0.20), −3.27 (0.90), and 0.25 (0.08), respectively. Alcohol consumption categories were positively associated with male sex, current smoking status, high education level, obesity, BMI, systolic and diastolic BP, uric acid, triglycerides, AST, ALT, and GGT, whereas they were inversely associated with age and platelet count. Nondrinkers were more likely to be older, regular exercisers, and to have diabetes mellitus and higher levels of hsCRP and HOMA-IR, but less likely to be current smokers. Table 2 shows the relationship of alcohol consumption categories with the risk of worsening of noninvasive fibrosis markers based on FIB-4, NFS, and APRI. During follow-up, the mean (SD) values were 0.72 (0.16) for FIB-4, −2.95 (0.74) for NAFLD score, and 0.26 (0.07) for APRI. Of 58,927 participants with NAFLD and a low probability of advanced fibrosis at baseline, the number of transition to intermediate and high fibrosis scores was 5,421 (9.2%) and 19 ). To explore whether inflammation or insulin resistance mediated the association of nonheavy alcohol consumption with worsening of noninvasive fibrosis markers, additional analyses were performed with adjustment for hsCRP and HOMA-IR. These associations did not change substantially after adjusting for hsCRP and HOMA-IR. When the association between alcohol consumption category and fibrosis progression was evaluated after introducing alcohol consumption and confounders as time-varying covariates, the association between moderate alcohol consumption and worsening of noninvasive fibrosis markers was still observed in time-dependent models. During follow-up, a total of 8 hepatocellular carcinomas (HCCs) were identified based on self-reported physician diagnosis. Due to the small number of HCC cases, additional analyses could not be performed to test the relationship between nonheavy drinking and HCC. The association between alcohol consumption category and worsening of FIB-4 score was similar across predetermined subgroups with no significant interactions (Table 3) .
In a series of sensitivity analyses to test the robustness of our primary results, moderate alcohol consumption was found to be consistently associated with a higher risk of worsening of noninvasive fibrosis markers. First, in the analysis using only high fibrosis score as an endpoint (instead of a composite endpoint of both intermediate and high fibrosis scores), the association between moderate alcohol consumption and progression from low to high fibrosis score was stronger. Multivariable-adjusted HRs (95% CI) for the development of high FIB-4 comparing light and moderate with nondrinkers as a reference were 1.48 (0.89-2.46) and 2.52 (1.51-4.20), respectively, whereas corresponding HRs (95% CI) for the development of high APRI were 1.40 (0.90-2.17) and 1.98 (1.24-3.15), respectively. Similarly, the risk for developing high NFS tended to be higher in those with moderate alcohol consumption, but this did not reach statistical significance (Supporting Table S1 ). Second, when the endpoint was defined as repeated observation at the subsequent follow-up visits after the first occurrence of the progression (from low to intermediate or high fibrosis scores), multivariable-adjusted HR (95% CI) for persistent worsening of FIB-4 comparing light and moderate drinkers with nondrinkers were 1.08 (0.91-1.27) and 1.33 (1.13-1.57), respectively, whereas the corresponding HRs (95% CI) for persistent worsening of NFS were 1.14 (1.02-1.27) and 1.37 (1.23-1.52), respectively (Supporting Table S2 ). Third, after excluding participants with regression of NAFLD based on follow-up ultrasonography, moderate alcohol consumption was still associated with a higher risk of worsening of noninvasive markers (Supporting Table S3 ). Fourth, to exclude the effects of binge drinking, analyses of participants who did not consume 60 g or more of alcohol on one occasion were performed (Supporting Table S4 ). Moderate drinkers still showed significantly higher risk of worsening of noninvasive fibrosis markers based on FIB-4 and NFS. Finally, in analysis using stabilized inverse probability weights, moderate drinkers had significantly increased risk for progression from low to intermediate or high fibrosis scores based on FIB-4 and NFS (Supporting Table S5 ).
Discussion
In this large cohort of 58,927 young and middle-aged Korean men and women with NAFLD, nonheavy alcohol consumption, especially moderate alcohol consumption, was significantly associated with increased risk for progression from low to intermediate or high fibrosis scores. This association remained significant after adjusting for potential confounders and was observed even when changes in alcohol consumption and confounders during follow-up were treated as time-varying covariates. Our study findings suggest that alcohol consumption adversely affects fibrosis progression in NAFLD even with moderate alcohol intake.
While some studies reported positive effects of moderate drinking on liver histology in NAFLD, other studies reported negative outcomes. Dunn et al. demonstrated that modest alcohol consumption was inversely associated with NASH and fibrosis stage in a cross-sectional analysis of 251 lifetime nondrinkers and 331 modest drinkers with biopsy-proven NAFLD. (10) Another study of 77 patients with biopsy-proven NAFLD showed a significant association between moderate alcohol consumption and less severe liver disease, including advanced fibrosis. (28) A study of 105 patients with morbid obesity underlying bariatric surgery demonstrated an association between moderate alcohol consumption and decreased prevalence of NASH, (11) while another cross-sectional study of 132 patients with morbid obesity did not. (12) However, these previous studies used a cross-sectional design which can be limited by temporal ambiguity between alcohol consumption and NAFLD severity as well as reverse causality bias. (9) Very recently, a longitudinal analysis of paired liver biopsies in patients with biopsy-proven NAFLD reported that modest alcohol consumption was associated with less improvement in steatosis and lower odds of NASH resolution but was not associated with changes in fibrosis stage compared with no use of alcohol. (29) In the present cohort study, nonheavy alcohol consumption was significantly and prospectively associated with a higher risk of worsening of noninvasive fibrosis markers. A binge drinking pattern can be another risk factor for fibrosis progression, even when the average alcohol intake falls into the moderate drinking category. (9, 25, 26) However, in our study, even when analysis was limited to nonbinge drinkers, moderate alcohol consumption was still significantly associated with an increased risk of worsening of fibrosis markers.
The exact mechanisms that link nonheavy alcohol consumption and fibrosis progression are not fully understood. The association between moderate alcohol consumption and development of NAFLD might primarily be mediated by altered peripheral insulin resistance. (30) In the present study, the association between nonheavy alcohol consumption and worsening of noninvasive fibrosis markers was observed even after adjustment for HOMA-IR and hsCRP. Indeed, ethanol has been shown to have many effects on the liver. It reaches the liver via the portal vein, induces triglyceride accumulation and hepatic oxidative stress in the liver, and also increases gut permeability. (31) Zhu et al. demonstrated that patients with NASH exhibit significantly elevated blood ethanol levels compared to those without NASH. (32) In a study using rats addressing the effect of low ethanol intake (16% of total calories) on the progression of a high-fat diet-induced NASH model, the researchers found increased numbers of inflammatory foci and apoptotic cells due to the additional intake of ethanol. (33) This suggests that moderate alcohol intake can augment inflammation as well as apoptosis in rodents with underlying NASH. (30, 33) Another experimental study using mice, alcohol, and a high-fat diet reported significantly enhanced proinflammatory gene expression, leading to marked induction of hepatic fibrosis. (34) Future studies are required to elucidate the mechanism of how moderate alcohol consumption is involved in fibrosis progression.
We note several limitations in our study. First, our study did not use liver biopsy to diagnose hepatic steatosis and fibrosis. However, liver biopsy is neither feasible nor ethical in this large-scale cohort study with a low-risk population. Abdominal ultrasound has acceptable diagnostic accuracy for the detection of fatty liver and is widely used in population-based epidemiological studies. (35) (36) (37) Noninvasive fibrosis indices, including NFS, FIB-4, and APRI, have been validated in a heterogeneous group of NAFLD patients as a correlate of advanced fibrosis confirmed by liver biopsy. (38, 39) Second, we could not evaluate the effects of different types of alcoholic beverages, lifetime drinking pattern (e.g, previous heavy drinking), occupation, caffeine intake or dietary pattern on fibrosis progression as there data were not available. Furthermore, information on use of specific medications that could affect liver fibrosis (e.g., thiazolinedione, renin angiotensin system inhibitors, and statins) was not available in this study. (40) (41) (42) Lastly, our study population included relatively young and middle-aged Koreans, possibly limiting generalizability to other age groups, populations with a higher prevalence of comorbidities, or other race/ethnic groups.
The strengths of our study are its prospective cohort study design; the use of carefully standardized clinical, imaging, and laboratory procedures; and inclusion of lifestyle factors, enabling us to account for possible confounders. The large sample size and repeated measures of alcohol consumption and other covariates enabled detection of moderate associations between nonheavy alcohol consumption with worsening of noninvasive fibrosis markers by considering changes in exposure status over time. While previous studies mainly included high-risk groups of patients referred because of elevated liver enzymes or clinical indications, selection bias might have been introduced by over-representation of patients with more severe disease. Our findings from a cohort of asymptomatic and relatively young adults potentially are less likely to be affected by survivor bias and biases related to comorbidities and use of multiple medications compared to findings from previous cohorts of patients with biopsy-proven NAFLD or NASH.
In this large cohort study of young and middle-aged adults with NAFLD, nonheavy alcohol consumption, especially moderate alcohol consumption, was positively associated with increased risk of worsening fibrosis markers, indicating that even moderate alcohol consumption might be harmful. Avoidance of alcohol should be included in preventive strategies for reducing fibrosis progression and associated consequences in individuals with NAFLD.
